Articles
8 June 2009
Vol. 2 No. 7: New Insights in Hematology, Venice (Italy), May 14-17, 2006
https://doi.org/10.4081/hmr.v2i7.415

Azacytidine: first therapeutic opportunity for myelodysplastic syndromes

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
232
Views
328
Downloads

Authors

C Finelli
support@pagepress.org
C Bosi
G Martinelli
M Baccarani
Myelodysplastic syndromes (MDS) are clonal disorders characterized by ineffective hematopoiesis, wich can lead either to fatal cytopenia or acute myelogenous leukemia (AML). During the last 14 years, important progress has been made in the understanding of the biology and prognosis of MDS; risk-adapted treatment strategies were estabilished, according to the median age (60-75 years ) of MDS patients and the individual history of the desease (number of cytopenias, cytogenetic changes, transfusion requirements).

Altmetrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite



Azacytidine: first therapeutic opportunity for myelodysplastic syndromes. (2009). Hematology Meeting Reports (formerly Haematologica Reports), 2(7). https://doi.org/10.4081/hmr.v2i7.415